Clinical Trial

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-31
Trial Details
NCT Number NCT07601425
Lead Sponsor Atavistik Bio, Inc
Conditions Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Enrollment 100 participants
Start Date 2026-06
Primary Completion 2027-12 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-30